The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
Discover how GLP-1 medications are impacting more than just physical health, influencing career opportunities and personal relationships for women in a remarkable new study.
Peptides are the newest buzzword in health and beauty, promising everything from wrinkle reduction to profound weight loss. But does the science actually back up the claims, and are they safe?
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
As GLP-1 medications become more accessible, older adults are asking: 'Am I too old?' This guide explores the nuances of using these powerful drugs for weight loss in seniors, emphasizing health over age.
Discover the single most important question to ask before starting GLP-1 medications like Ozempic or Wegovy. Learn how to ensure sustainable weight loss and avoid the common pitfalls of viewing these drugs as a magic cure.
Peptide therapy is rapidly gaining traction far beyond the well-known GLP-1 medications. This deep dive explores the science, the 'health-maxing' movement, supply chain complexities, and the crucial regulatory landscape shaping the future of these powerful compounds.
For years, Medicare's stance on GLP-1 medications for weight loss was a firm 'no.' However, a significant shift is underway. Discover how the new 'Bridge' program opens doors to crucial weight management tools like Wegovy and Mounjaro, and what you need to know.
The collision of rapid weight loss driven by GLP-1 medications like Wegovy and Mounjaro with the natural bone density decline of menopause creates a significant, under-discussed risk for women's skeletal health.
